

# Estradiol-induced senescence of hypothalamic astrocytes contributes to aging-related reproductive function declines in female mice

Xiaoman Dai<sup>1,\*</sup>, Luyan Hong<sup>1,3,\*</sup>, Hui Shen<sup>1,\*</sup>, Qiang Du<sup>2</sup>, Qinyong Ye<sup>1</sup>, Xiaochun Chen<sup>1</sup>, Jing Zhang<sup>1</sup>

<sup>1</sup>Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350001, Fujian, China

<sup>2</sup>Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, China

<sup>3</sup>Department of Biochemistry and Molecular Biology, Gannan Medical University, Ganzhou 341000, Jiangxi, China

\*Equal contribution

**Correspondence to:** Jing Zhang, Xiaochun Chen; **email:** [drzj@163.com](mailto:drzj@163.com), [chenxc998@fjmu.edu.cn](mailto:chenxc998@fjmu.edu.cn)

**Keywords:** estradiol, aging, hypothalamic astrocyte, reproduction, GnRH

**Received:** November 25, 2019

**Accepted:** January 27, 2020

**Published:** April 7, 2020

**Copyright:** Dai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

Hypothalamic astrocytes are important contributors that activate gonadotropin-releasing hormone (GnRH) neurons and promote GnRH/LH (luteinizing hormone) surge. However, the potential roles and mechanisms of astrocytes during the early reproductive decline remain obscure. The current study reported that, in intact middle-aged female mice, astrocytes within the hypothalamic RP3V accumulated senescence-related markers with increasing age. It employed an ovariectomized animal model and a cell model receiving estrogen intervention to confirm the estrogen-induced senescence of hypothalamic astrocytes. It found that estrogen metabolites may be an important factor for the estrogen-induced astrocyte senescence. In vitro molecular analysis revealed that ovarian estradiol activated PKA and up-regulated CYPs expression, metabolizing estradiol into 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>. Of note, in middle-aged mice, the progesterone synthesis and the ability to promote GnRH release were significantly reduced. Besides, the expression of growth factors decreased and the mRNA levels of proinflammatory cytokines significantly increased in the aging astrocytes. The findings confirm that ovarian estradiol induces the senescence of hypothalamic astrocytes and that the senescent astrocytes compromise the regulation of progesterone synthesis and GnRH secretion, which may contribute to the aging-related declines in female reproductive function.

## INTRODUCTION

Age-related female reproductive decline is associated with the neuroendocrine regulation of the hypothalamic-pituitary-ovarian axis (HPO), in which an attenuated luteinizing hormone (LH) surge is one of the earliest signs associated with reproductive senescence in female rats and mice [1, 2]. Previous research has documented that the activation of gonadotropin-releasing hormone (GnRH) neurons is remarkably reduced in middle-aged

mice during the GnRH/LH surge [3–5]. However, the underlying mechanisms of the hypothalamic regulation for the early reproductive decline remain obscure.

To date, a body of studies have documented that hypothalamic astrocytes are one of the key cells that constitute the neural circuits responsible for GnRH neuron activation and GnRH release. Studies in rodents have shown that ovarian estradiol (E<sub>2</sub>) stimulates progesterone synthesis in hypothalamic astrocytes,

which is the key to the activation of the GnRH neurons [6–8]. Specifically, estradiol acts on membrane-associated estradiol receptor- $\alpha$  (ER $\alpha$ ) in astrocytes to increase the release of intracellular store of Ca<sup>2+</sup> via a phospholipase C (PLC)/ inositol trisphosphate (IP3) signaling pathway. The increased Ca<sup>2+</sup> level in turn activates the protein kinase A (PKA), leading to protein phosphorylation and the activation of cholesterol-side-chain cleavage enzyme (P450scc) and 3 $\beta$ -hydroxysteroid dehydrogenase (3 $\beta$ -HSD), which are responsible for limiting the rate of progesterone synthesis. Then, the newly synthesized progesterone then diffuses out of the astrocytes and activates estradiol-induced progesterone receptors in proximal neurons, triggering the neural cascades and resulting in the GnRH/LH surge [6].

Available studies have also demonstrated that astrocytes are essential for the GnRH neuronal activity and GnRH release through multiple pathways. In rodents and rhesus monkeys, the remarkable structural plasticity of astrocytes has been confirmed to ensheath GnRH cell bodies and/or to oppose the GnRH processes. These structural relationships are dynamically regulated by ovarian estradiol and are crucial for normal female reproductive function [9–11]. In addition, astrocytes also synthesize and release cytokines that regulate GnRH secretion, including prostaglandin E and a lot of growth factors, such as transforming growth factors (TGF $\alpha$  and TGF- $\beta$ 1), basic fibroblast growth factor IGF1, and epidermal growth factor family, etc. [12–15].

Taken together, the existent literature shows that astrocytes play a crucial part in the puberty onset, estrus cycle, and fertility [7, 8, 16]. But what changes take place in the hypothalamic astrocytes during aging remains blurred. Therefore, we hypothesized that when the repeated cycles of ovarian estradiol induce the synthesis of neuroprogesterone in hypothalamic astrocytes, the metabolic pathway of estradiol also simultaneously accelerates the senescence of astrocytes, which would weaken or change the role of astrocytes in regulating the female reproductive function. We tested this hypothesis with a mouse model receiving bilateral ovariectomy and an estradiol replacement and in vitro primary cultured hypothalamic astrocytes treated with estradiol.

## RESULTS

### **Astrocytes within the hypothalamic RP3V accumulate senescence-related markers with increasing age**


To observe the age-related changes of astrocytes in the rostral periventricular area of the third ventricle (RP3V)

of the hypothalamus, the senescence-related markers of the astrocytes were compared between the young-aged and middle-aged group with regular estrous cycles. The senescence was evaluated by measuring the level of lipofuscin granules, a constant and reliable indicator of cell senescence [17]. Under an electron microscope, the number and volume of lipofuscin granules of hypothalamic astrocytes in the middle-aged group increased markedly (Figure 1A). A subsequent confirmation by senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -Gal) staining [18] combined with GFAP (astrocyte marker) immunohistochemistry reported an obviously higher percentage of SA- $\beta$ -gal positive astrocytes in the middle-aged group than in young-aged mice (df=16; t=23.68;  $p<0.01$ ) (Figure 1B). DAB staining was performed to detect the peroxidase activity and revealed an increased peroxidase activity in the middle-aged mice (Figure 1C). A further labeling of GFAP by immunohistochemistry showed a much higher percentage of peroxidase-positive astrocytes in the middle-aged mice than in the young ones (Unpaired t test, df=17; t=7.664;  $p<0.01$ ) (Figure 1C). Finally, immunofluorescence was performed to detect in astrocytes the expression of p16 and  $\gamma$ -H<sub>2</sub>AX, which are the respective markers for senescence and DNA injury and are usually highly expressed in the senescent cells [19–21]. The analysis showed that compared with those of the young-aged mice, the mean fluorescence intensity of p16 and that of  $\gamma$ -H<sub>2</sub>AX in the astrocytes of the RP3V were both significantly enhanced in the middle-aged mice (Unpaired t test, df=30; t=9.44;  $p<0.01$ ; df=8; t=3.492;  $p<0.01$ , respectively) (Figure 1D). These results show that astrocytes in the hypothalamic RP3V display age-related senescence.

To further confirm the type of senescent cells, Iba1 (a microglia marker) staining by immunohistochemistry was performed after the completion of SA- $\beta$ -Gal staining, which found no SA- $\beta$ -Gal positive microglia cells in the middle-aged mice (Figure 1E). To explore whether the senescence of astrocytes is selective in brain regions, SA- $\beta$ -Gal staining was also performed on the hippocampal and cortical region of the middle-aged female C57BL/6J mice. The results showed no obvious senescent characteristics in the astrocytes of these two brain regions (Figure 1E). These findings suggest that the senescence of astrocytes in the middle-aged mice is selective in brain regions.

### **Estradiol induces the senescence of astrocytes in the hypothalamus**

As astrocytes in the hypothalamic RP3V play a crucial part in the estradiol positive feedback [16, 22, 23], it follows that the senescence of astrocytes in RP3V may be associated with ovarian estradiol. To confirm this



**Figure 1. Astrocytes within the hypothalamic RP3V accumulates senescence-related markers with increasing age.** (A) The lipofuscin deposition by transmission electron microscopy in hypothalamic astrocytes of female C57BL/6J mice at the age of 3 months and 10 months. Black arrows represent the lipofuscin deposition. (B) Dual-label immunohistochemistry of astrocytes by GFAP staining (brown) and by SA-β-Gal staining (blue) in 3-month-old mice (n=5) and 10-month-old mice (n=5), black arrows representing SA-β-Gal –positive astrocytes, scale bar=50μm. (C) Peroxidase staining (brown) in the astrocytes of RP3V (left), black arrows representing peroxidase. GFAP (black) and peroxidase (brown) double staining in astrocytes of RP3V in the hypothalamus of 3-month-old mice (n=5) and 10-month-old mice (n=5), black arrows representing peroxidase–positive astrocytes, scale bar =100μm. (D) Dual-label immunofluorescence showing astrocytes (green) with p16 (red) in young (n=5) and middle-aged mice (n=5), white arrows representing p16–positive astrocytes, scale bar=100μm (left). Dual-label immunofluorescence showing astrocytes (green) with  $\gamma$ -H2AX (red) in young (n=5) and middle-aged mice (n=5), white arrows representing  $\gamma$ -H2AX–positive astrocytes, scale bar=25μm (right). (E) Dual-label immunohistochemistry showing astrocytes (brown) with SA-β-Gal staining (blue) in 10-month-old mouse cortex (left picture) and hippocampal (top right picture). Dual-label immunohistochemistry showing microglia (brown) with SA-β-Gal staining (blue) in RP3V of 10-month-old mice (bottom right picture). Scale bar=100μm. The *p*-value was determined by Student’s t test,\*\* *p* < 0.01. RP3V, i.e. rostral periventricular area of the third ventricle; GS, i.e. glutamine synthetase.



hypothesis, a mouse model with ovarian resection was adopted in the study. A total of 45 female mice (aged 3 months old) with regular estrus cycles determined by daily vaginal smears were selected and randomly placed into 3 groups receiving bilateral ovariectomy (OVX group), bilateral ovariectomy plus estradiol replacement (OVX+E<sub>2</sub> group) or sham-operation (control group). The OVX+E<sub>2</sub> group received twice a 0.25mg dose of a 90-day sustained release pellet of 17 $\beta$ -estradiol placed subcutaneously. The dose of the 17 $\beta$ -estradiol in mice has been found to correspond to the estradiol levels in a pro-estrus phase [24, 25]. Brain tissue samples were obtained from the three groups when they were raised to 9 months old (Figure 2A). Compared with those of the sham group and OVX+E<sub>2</sub> group, the number of SA- $\beta$ -gal positive astrocytes in the RP3V of the OVX group was significantly reduced, and the mean fluorescence intensity of astrocytes expressing  $\gamma$ -H<sub>2</sub>AX and p16 was also obviously attenuated. Meanwhile, no significant difference was evident between the OVX+E<sub>2</sub> and the sham group (one-way ANOVA effect of treatment  $p=0.0944$ ,  $df=2,10$ ,  $F=3.895$ ;  $p=0.5026$ ,  $df=2,81$ ,  $F=0.4641$ ;  $p=0.6268$ ,  $df=2,42$ ,  $F=1.614$ ; respectively) (Figure 2B). The results show that the sustaining effect of estradiol is involved in the senescence of astrocytes in the hypothalamic RP3V.

To further confirm the above results, primary cultured astrocytes from the neonatal mouse hypothalamus were directly treated with 17 $\beta$ -estradiol. The intervention concentration of estradiol was 10<sup>-6</sup>M, 10<sup>-8</sup>M, and 10<sup>-10</sup>M, according to the experimental results of CCK8 (Supplementary Figure 1B). The astrocytes were first cultured with a carbon-adsorbed serum, which did not contain steroid hormones, for 24h before the 17 $\beta$ -estradiol intervention, and then incubated with different estradiol concentrations for 48 h. The process was repeated 4 times to induce cell senescence [6] (Figure 2C). The analysis showed that compared with the solvent-treated astrocytes, estradiol augmented the number of SA- $\beta$ -Gal positive astrocytes in the hypothalamus in a concentration-dependent manner. The number of  $\gamma$ -H<sub>2</sub>AX positive astrocytes and the mean fluorescence intensity of  $\gamma$ -H<sub>2</sub>AX expression in astrocytes were significantly enhanced in the estradiol-treated group (10<sup>-8</sup>M and 10<sup>-6</sup>M) (one-way ANOVA effect of treatment  $p<0.05$ ,  $df=3,11$ ,  $F=1.219$ ; Kruskal-Wallis test,  $p<0.01$ , respectively) (Figure 2D). In addition, the mRNA levels of *p16* and *p21* in the estradiol-treated group were significantly higher than those in the control sample (one-way ANOVA effect of treatment  $p<0.05$ ,  $df=3,10$ ,  $F=2.391$ ;  $p<0.05$ ,  $df=3,9$ ,  $F=1.525$ , respectively) (Figure 2E). However, estradiol treatment did not induce a similar phenomenon in the cortex-derived astrocytes but displayed an opposite change instead, as shown in the supplemental materials


(Supplementary Figure 1C–1E). Altogether, the results of in vivo and in vitro analyses show that estradiol induces the senescence of hypothalamic astrocytes.

### The estradiol metabolites 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> are closely associated with astrocyte senescence

To understand the mechanism of estradiol-induced cellular senescence, we investigated into the intracellular metabolic pathway of estradiol [26]. Estradiol metabolism operates in two pathways (Figure 3A): a conjugative pathway, which forms sulfates and glucuronides, respectively catalyzed by sulfotransferases (SULTs) and UDP-glucuronosyl transferases (UGTs), and a hydroxylated pathway. In the latter, estradiol is hydroxylated by CYPs (cytochrome p450) isoforms, including *CYP1A1*, *CYP1A2*, and *CYP1B1*, to form catechol estradiols, such as 2-hydroxyestradiol (2-OHE<sub>2</sub>) and 4-hydroxyestradiol (4-OHE<sub>2</sub>), which have long been thought to be an intermediate metabolite responsible for DNA damage and oxidative stress [27, 28]. So targeted HPLC was proceeded on hypothalamic tissues to examine the level of 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> and the results indicated their existence in the hypothalamus of the 10-month-old mice (Figure 3B). Furthermore, the primary cultured astrocytes from the hypothalamus were respectively treated with 2-OHE<sub>2</sub> (20nM, 24h) and 4-OHE<sub>2</sub> (20nM, 24h). The mean fluorescence intensity of p16 and  $\gamma$ -H<sub>2</sub>AX in the astrocytes treated with hydroxyl estradiols significantly increased when compared with that of the control group (one-way ANOVA effect of treatment  $p<0.01$ ,  $df=2,96$ ,  $F=0.5358$ ; Kruskal-Wallis test,  $p<0.01$ , respectively) (Figure 3C). Similarly, the mRNA level of *p16* and *p21* in the astrocytes treated with hydroxyl estradiols was obviously higher than that of the control group (one-way ANOVA effect of treatment  $p<0.01$ ,  $df=2,6$ ,  $F=1.982$ ;  $p<0.01$ ,  $df=2,6$ ,  $F=1.33$ , respectively) (Figure 3D). These results suggest that the intracellular metabolites of estradiol, 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>, facilitate the astrocyte senescence.

### PKA-CYP signaling mediates estradiol-induced senescence of hypothalamic astrocytes

CYPs are the key enzymes in the metabolism of estradiol into hydroxyl estradiols. It is reported that estradiol activates the protein kinase A (PKA) pathway to promote neuroprogesterone synthesis in the hypothalamic astrocytes, and that PKA can enhance the expression of CYPs in tumor cell models [29, 30]. Therefore, the activation of the PKA-CYPs pathway was examined in both the in vivo animal model and the in vitro primary cultured hypothalamic astrocytes. In the young mice with regular estrous cycle, the phosphorylation of PKA in the hypothalamus was



**Figure 2. Estradiol induces senescence of astrocytes in the hypothalamus.** (A) The flow chart of mouse castration and estradiol intervention. (B) Representative microscopies showing SA-β-gal staining in the control (n=5), OVX (n=5) and OVX+E<sub>2</sub> groups (n=5), black arrows representing SA-β-Gal-positive cells (left one). Dual-label immunohistochemistry showing astrocytes by GFAP staining (brown) and by SA-β-Gal staining (blue), black arrows representing SA-β-Gal-positive astrocytes (left two). Dual-label immunofluorescence showing astrocytes (green) with γ-H2AX (red), white arrows representing γ-H2AX-positive astrocytes (right two). Dual-label immunofluorescence showing astrocytes (green) with p16 (red), white arrows representing p16-positive astrocytes (right one). Scale bar= 100μm. (C) The flow chart of estradiol intervention in primary cultured astrocytes. (D) Dual-label immunohistochemistry showing astrocytes by GFAP staining (brown) and by SA-β-Gal staining (blue)

with three different estradiol concentrations ( $10^{-10}$ M,  $10^{-8}$ M,  $10^{-6}$ M) (upper), black arrows representing SA- $\beta$ -Gal-positive astrocytes. Scale bar=100  $\mu$ m. Dual-label immunofluorescence showing astrocytes (green) and  $\gamma$ -H2AX (red) with different estradiol concentrations, white arrows representing  $\gamma$ -H2AX-positive astrocytes. Scale bar=50 $\mu$ m. (E) Detection of *p16* and *p21* mRNA levels under different estradiol concentrations. Estradiol increased the expression of *p16* and *p21* with different estradiol concentrations in hypothalamic astrocytes ( $n = 3-4$ ). The experiments used two-way analysis of variance. The  $p$ -value was determined by One-way ANOVA: \* $p < 0.05$ , \*\*  $p < 0.01$ . OVX, i.e. ovariectomy, OVX+E<sub>2</sub>, i.e. ovariectomy plus estradiol replacement,  $10^{-6}$ M E<sub>2</sub>, i.e.  $10^{-6}$ M estradiol concentrations.

significantly higher during proestrus than during metestrus (Unpaired t test,  $df=10$ ;  $t=10.04$ ;  $p < 0.01$ ) (Figure 4A); Similarly, the mRNA level of the three subunits of the *CYP* gene (*CYP11A1/CYP11A2/CYP11B1*) during proestrus was also obviously higher than that during metestrus (Figure 4B). In the ovariectomized mice, the mRNA level of *CYP11A1*, *CYP11A2*, and *CYP11B1* in the OVX group was significantly lower than that in the control and OVX+E<sub>2</sub> groups, while no significant difference was evident between the control and OVX+E<sub>2</sub> groups (Figure 4C). In primary cultured hypothalamic astrocytes, the estradiol treatment ( $10^{-6}$ M) obviously improved the phosphorylation level of PKA (one-way ANOVA effect of treatment  $p < 0.01$ ,  $df=3,11$ ,  $F=1.297$ ) (Figure 4D) and the mRNA expression of *CYP* subunits (Figure 4E). In contrast, no similar phenomenon was observed in the primary cultured cortical astrocytes treated with estradiol (Supplementary Figure 2A). Moreover, the cultured hypothalamic astrocytes were further respectively treated with Forskolin, an agonist for PKA, and H-89, an inhibitor for PKA. A 24-hour treatment with H-89 (10 $\mu$ M) decreased the expression of CYPs; however, a 24-hour treatment with Forskolin (30 $\mu$ M) significantly upregulated CYPs level (Figure 4F). These data indicate that estradiol activates the PKA pathway and then up-regulates the expression of CYPs in hypothalamic astrocytes.

To clarify the role of the PKA pathway in activating CYPs in the estradiol-induced senescence of hypothalamic astrocytes, the primary cultured hypothalamic astrocytes were respectively treated with the PKA inhibitor and agonist alone and with estradiol ( $10^{-6}$ M). The interventions were divided into the following six groups: the vehicle group,  $10^{-6}$ M E<sub>2</sub> group, H89 group (10 $\mu$ M, 24h), H89+ $10^{-6}$ M E<sub>2</sub> group, Forskolin group (30 $\mu$ M, 24h), and Forskolin+ $10^{-6}$ M E<sub>2</sub> group. After four consecutive 17 $\beta$ -estradiol interventions, no significant difference in the percentage of SA- $\beta$ -Gal positive astrocytes was found among the vehicle group, H89 group and Forskolin group. Of note, the percentage of senescent astrocytes was prominently higher in Forskolin+ $10^{-6}$ M E<sub>2</sub> group than in Forskolin group and  $10^{-6}$ M E<sub>2</sub> group. On the contrary, H89 treatment obviously decreased the E<sub>2</sub>-induced senescent astrocytes (one-way ANOVA effect of treatment  $p < 0.01$ ,  $df=5,23$ ,  $F=1.668$ ) (Figure 4G). Taken together, these results suggest that the activation of CYPs by


PKA is a key pathway for the estradiol-induced senescence of hypothalamic astrocytes.

### **Estradiol-induced senescence of hypothalamic astrocytes contributes to aging-related declines in female reproductive function**


A body of studies have suggested that hypothalamic astrocytes are involved in regulating the production of endogenous progesterone and GnRH secretion. Therefore, we detected the level of progesterone by HPLC. The results showed that the progesterone level in the hypothalamus of the young-aged mice was significantly higher than that of the 10-month-old mice (Unpaired t test,  $df=4$ ;  $t=7.193$ ;  $p < 0.01$ ) (Figure 5A). The key rate-limiting enzymes in progesterone synthesis, *P450scc* and *3 $\beta$ -HSD*, were further quantified by qPCR (Figure 5B). In 3-month-old mice, the mRNA levels of *P450scc* and *3 $\beta$ -HSD* were significantly higher during proestrus than during metestrus, which was not found in 10-month-old mice. Moreover, during proestrus, the mRNA expression of *P450scc* in the 10-month-old mice was obviously lower than that in 3-month-old mice. Particularly, during metestrus, the mRNA expression of *3 $\beta$ -HSD* in the middle-aged mice was significantly higher than that in the young ones. To investigate the effect of senescence astrocyte on GnRH secretion, the conditional medium derived from 2-OHE<sub>2</sub>- or 4-OHE<sub>2</sub>-induced aging astrocytes was collected and used to treat the hypothalamic cell line GT1-7. It showed that aging astrocyte conditioned-medium (AACM) prominently decreased the secretion of GnRH when compared with the control group (one-way ANOVA effect of treatment  $p < 0.05$ ,  $df=2,6$ ,  $F=1.297$ ) (Figure 5C).

The exact existence of a humoral communication between glial cells and GnRH neurons has been studied using the GT1-7 cell line and astrocytes. Studies have indicated that growth factors IGF1, TGF $\alpha$  and TGF $\beta$ 1 released from the primary astrocyte culture participate in the cross talk between GnRH neurons and astrocytes [13–15]. qPCR results showed that during metestrus, the mRNA level of TGF $\alpha$  and IGF1 of the middle-aged mice was obviously decreased when compared with that of the young-aged mice, with no obvious difference in TGF $\beta$ 1 expression (Figure 5E). In addition, the expression of the three genes declined significantly when the primary cultured astrocytes were treated with





**Figure 3. The estradiol metabolites 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> are closely associated with astrocyte senescence.** (A) The flow chart of estradiol metabolism. (B) HPLC chromatogram of 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> in hypothalamic tissue of 10-month-old mice. (C) Dual-label immunofluorescence showing astrocytes (green) and p16 (red) with 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>, white arrows representing  $\gamma$ H2AX-positive astrocytes (left). Dual-label immunofluorescence showing astrocytes (green) and  $\gamma$ H2AX (red) with 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>, white arrows representing  $\gamma$ H2AX-positive astrocytes (right). Scale bar= 100  $\mu$ m. (D) Detection of *p16* and *p21* mRNA levels with 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> intervention. 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> respectively increased the expression of *p16* and *p21* in hypothalamic astrocytes (n=3). The *p*-value was determined by One-way ANOVA: \*\* *p* < 0.01.



**Figure 4. PKA-CYP signaling mediates estradiol-induced senescence of hypothalamic astrocytes.** (A) The expression of PKA and p-PKA in hypothalamus during proestrus and metestrus at 3 months of age as determined by Western blotting (n = 6). (B) Effects of estrous cycle on the mRNA expression of *CYP1A1*, *CYP1A2* and *CYP1B1* gene in the hypothalamus as determined by qPCR. Metestrus vs. proestrus, n=3 (upper). (C) Effects of estradiol on the mRNA expression of *CYP1A1*, *CYP1A2* and *CYP1B1* gene in the hypothalamic tissue as determined by qPCR. OVX group vs. control group, OVX group vs. OVX+E<sub>2</sub> group, n=3. The p-value of (A–C) was determined by Student's t test, \*p<0.05, \*\*



$p < 0.01$ . (D) Expression of PKA and p-PKA in primary cultured hypothalamic astrocytes with the intervention of different estradiol concentrations as determined by Western blotting ( $n = 5$ ). (E) Effects of estradiol on the mRNA expression of *CYP1A1*, *CYP1A2* and *CYP1B1* gene in primary cultured hypothalamic astrocytes with the intervention of different estradiol concentrations, as compared with the control,  $n = 3$ . (F) Effects of PKA activator (Forskolin,  $10\mu\text{M}$ , 24h) and inhibitor (H89,  $30\mu\text{M}$ , 24h) on the mRNA expression of *CYP1A1*, *CYP1A2* and *CYP1B1* gene in the primary cultured hypothalamic astrocytes, as compared with the control,  $n = 3$ . (G) Dual-label immunohistochemistry showing astrocytes (brown) and SA- $\beta$ -Gal staining (blue) with the effects of  $10^{-6}\text{M}$  estradiol, together with Forskolin and H89, respectively. Black arrows represent SA- $\beta$ -Gal –positive astrocytes.  $n = 3$ , scale bar =  $50\mu\text{m}$ . The  $p$ -value was determined by One-way ANOVA: \* $p < 0.05$ , \*\*  $p < 0.01$ . FSK, i.e. forskolin.

2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> while no expression difference was found when they were treated with different concentrations of estradiol. It has been reported that inflammatory pathways may impair the central regulatory networks involving GnRH neuron activity [31, 32]. However, the precise cellular and molecular effects of inflammatory factors secreted by the senescent astrocytes on GnRH neurons have not been reported yet. To gain a better insight into these regulations, the level of inflammatory cytokines was further quantified by qPCR in vivo and in vitro (Figure 5D). Not surprisingly, regardless of proestrus or metestrus, the mRNA level of inflammatory cytokines (*TNF- $\alpha$* , *IL-1 $\beta$*  and *IL-6*) in the middle-aged mice markedly increased when compared with that of the young-aged mice. During proestrus, the mRNA expression of *IL-8* in the middle-aged mice was significantly higher than that in young-aged mice. Interestingly, repeated 17 $\beta$ -estradiol treatments significantly enhanced the mRNA level of *TNF- $\alpha$* , *IL-1 $\beta$* , *IL-6* and *IL-8* in the cultured hypothalamic astrocytes. Together, these data suggest that the reduction of progesterone and neurotrophic factors, together with the elevation of inflammatory factors in senescent astrocytes, contributes to aging-related declines in female reproductive function.


## DISCUSSION

This research found that astrocytes within the hypothalamic RP3V, not in the cortex and hippocampus, accumulate senescence-related markers with increasing age; that this cellular senescence is closely related to ovarian estradiol and compromises the regulation of progesterone synthesis and GnRH secretion. The molecular mechanism revealed that the PKA-CYPs signaling metabolized intracellular estradiol into 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>, which were involved in the astrocyte senescence within RP3V.

It has been reported that hypothalamic astrocytes facilitate the estrogen positive feedback [7, 8, 16, 33]. The current study confirms the relationship between the estrogen positive feedback and the aging of hypothalamic astrocytes from the following three aspects. The age-dependent changes of the senescent markers of astrocytes within RP3V in intact female

mice were investigated (Supplementary Figure 1A). We found that the number of peroxidase staining and SA- $\beta$ -Gal-positive astrocytes increased gradually from 3 months to 9 months of age, while almost no senescent astrocytes were observed at 1 month and 2 months of age. In rodents, reproductive function is fully developed at 3 months old, accompanied by regular estrous cycles. Therefore, we also tested the effect of ovarian-derived estradiol on the senescence of hypothalamic astrocytes. In the current study, the senescent characteristics of astrocytes in RP3V of the ovariectomized 3-month-old female mice were significantly reduced (Figure 2A, 2B). In addition, to mimic the positive feedback effect of estradiol in the body, the primary cultured hypothalamic astrocytes were repeatedly interfered with different concentrations of estradiol ( $10^{-10}\text{M}$ ,  $10^{-8}\text{M}$ , and  $10^{-6}\text{M}$ ), in which  $10^{-6}\text{M}$  estradiol for 48h has been demonstrated to induce progesterone secretion in hypothalamic astrocytes [6] and  $10^{-10}\text{M}$  estradiol is equivalent to the basic estradiol level in the normal cycle [34, 35]. As we expected, four consecutive estradiol interventions induced the senescence of hypothalamic astrocytes (Figure 2C–2E) but the phenomenon was not found in the cultured astrocytes from the cortex (Supplementary Figure 1C–1D). These results suggest that ovarian estradiol is closely related to the senescence of hypothalamic astrocytes, which is consistent with previous reports [36, 37].

Estradiol promotes the synthesis of progesterone in astrocytes by activating the cAMP/PKA pathway. Consistent with literature reports [6, 8, 38], compared with that during metestrus, the phosphorylation of PKA and mRNA level of *P450scc* and *3 $\beta$ -HSD* during proestrus significantly increased in the 3-month-old mice (Figures 4A and 5B). Therefore, we speculate that the PKA-CYPs pathway is involved in estradiol-induced senescence of hypothalamic astrocytes and put it to verification. In further experiments, estradiol significantly upregulated the phosphorylation of PKA and mRNA level of *CYPs* subunits in scenarios both in vivo (Figure 4A–4C) and in vitro (Figure 4D–4E). Moreover, the metabolization of estradiol into catechol estradiols by *CYPs* promoted oxidative damage to the hypothalamus. We found that 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> were present in the hypothalamus of the 10-month-old mice and that a low dose of 2-OHE<sub>2</sub> or 4-OHE<sub>2</sub> induced the



**Figure 5. Estradiol-induced senescence of hypothalamic astrocytes contributes to aging-related declines in female reproductive function.** (A) HPLC chromatogram of standard progesterone (left) and hypothalamic tissue extract of 3-month-old and 10-month-old mice. The  $p$ -value was determined by Student's  $t$  test: \*\*  $p < 0.01$ ,  $n = 3$ . (B) Effects of estrous cycle and age on the levels of *P450scc* and *3β-HSD* mRNA in hypothalamus as determined by qPCR. The  $p$ -value was determined by Two-way ANOVA: \*\*  $p < 0.01$ ,  $n = 3$ . (C) Both 2-


OHE<sub>2</sub>-ACM and 4-OHE<sub>2</sub>-ACM inhibited the secretion of GnRH from GT1-7 cells. The *p*-value was determined by One-way ANOVA: \**p*<0.05, *n*=3-4. (D) Effects of estrous cycle and age on the levels of *TNF-α*, *IL-1β*, *IL-6* and *IL-8* mRNA in hypothalamus as determined by qPCR. The *p*-value was determined by Two-way ANOVA: \**p*<0.05, \*\* *p*< 0.01, *n* = 3 (upper). Effects of estradiol on the levels of *TNF-α*, *IL-1β*, *IL-6* and *IL-8* mRNA in hypothalamic primary cultured astrocytes as determined by qPCR (*n*=3-6). The *p*-value was determined by One-way ANOVA: \**p*<0.05, \*\* *p*< 0.01 (blew). (E) Effects of estrous cycle and age on the levels of *TGF-α*, *TGF-β1*, and *IGF1* mRNA in hypothalamus as determined by qPCR (*n* = 3). The *p*-value was determined by Two-way ANOVA: \**p*<0.05, \*\* *p*< 0.01 (upper). Detection of *TGF-α*, *TGF-β1*, and *IGF1* mRNA levels with 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> intervention (*n*=3). The *p*-value was determined by One-way ANOVA: \**p*<0.05, \*\* *p*< 0.01.

senescence of cultured hypothalamic astrocytes (Figure 3). These findings are in line with the conclusion of the damage of catechol estradiols to DNA [27, 28]. Still, the regulation of PKA activity affected the estradiol-induced senescence of hypothalamic astrocytes (Figure 4G). In this study, we tried to use CYPs inhibitors to investigate whether it can inhibit the estradiol-induced astrocyte senescence. Unfortunately, CYPs are composed of multiple subtypes, and commercial CYPs inhibitors are currently not effective in inhibiting all subtypes. We expect to use CYPs blockers to prevent the senescence of hypothalamic astrocytes in the future.

Within more than two decades, many studies have shown that estradiol has a clear neuroprotective effect on AD, PD and stroke et al [39–42]. Our current conclusions concerning estradiol in the cortex do not contradict previous reports. In our study, ovarian estradiol selectively induced the senescence of hypothalamic astrocytes, not those in the hippocampus or cortex. The activation of the PKA pathway by estradiol not only mediates the process of progesterone

synthesis but also up-regulates the activation of the CYPs pathway, promoting the catechin metabolism of estradiol. Of note, the activation of the PKA-CYPs pathway has not been found in the cortex during positive feedback effect of estradiol during metestrus and proestrus period (Supplementary Figure 2B, 2C). Further experimentation is needed to explore the underlying reasons for the differential activation of the PKA pathway in astrocytes from distinct brain regions.

What interests us most is the functional changes that may result from the senescent astrocytes. As expected, in the middle-aged mice, not only the level of progesterone but also the key enzyme of progesterone synthesis (P450<sub>scc</sub>) were significantly lower than those of the young mice. Another enzyme of progesterone synthesis (3β-HSD) was up-regulated instead, which may be a consequence of estradiol treatment [43]. Unfortunately, we have not been able to detect directly the progesterone level in the estradiol-induced senescent astrocytes, due to technical limitations, and used HPLC instead. When GT1-7 was incubated with the



**Figure 6. A model of estradiol action on hypothalamic astrocytes involving the progesterone production on the basis of present results and previous findings.** Circulating estradiol acts on astrocytes that regulate progesterone (PROG) synthesis to activate the cAMP-PKA pathway. PKA can phosphorylate cytochrome P450<sub>scc</sub> and 3β-HSD, which regulate PROG production. The activated PKA pathway can also increase the expression of CYPs genes, which participate in the process of estradiol metabolism. Metabolic products of estradiol, 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>, exert strong oxidative stress on astrocytes. ER, i.e. estrogen receptor; CHOL, i.e. cholesterol.



conditional culture medium of astrocytes (CCMA) that were pretreated by catechin estradiols, the level of GnRH secreted by GT1-7 was obviously reduced (Figure 5C). However, the pretreatment of CCMA with the different concentrations of estradiol did not cut down the GnRH level (data not shown). We speculate that the degree of estradiol-induced senescence in astrocytes is not as serious as that by catechin estradiols (Supplementary Figure 3A). Similarly, we only detected a decrease of growth factors, *TNF- $\alpha$*  and *IGF1*, both in animal models of different ages and the cellular model receiving 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> interventions, but not in the cellular model receiving estradiol intervention. Studies have shown that a high expression of *IL-6* and *IL-1 $\beta$*  can inhibit the secretion of GnRH in the hypothalamus, which in turn affects the reproductive function [32, 44]. Our study found that, regardless of proestrus or metestrus, the transcription levels of *IL-1 $\beta$* , *TNF- $\alpha$* , and *IL-6* were significantly higher in 10-month-old mice than in their 3-month-old counterparts, respectively. These data suggest that the aging of astrocytes in the hypothalamus is implicated in the decline of GnRH neuronal activation and GnRH release.

In summary, this study shows that astrocytes within the hypothalamic RP3V accumulate senescence-related markers with increasing age, accompanied by a decreased progesterone production, reduced ability of GnRH neurons to secrete GnRH, decreased production of growth factors, and increased levels of pro-inflammatory cytokines. The underlying mechanism involves the activation of PKA-CYPs pathway by ovarian estradiol, promoting the metabolism of estradiol into 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> and accelerating the astrocyte senescence within RP3V (Figure 6). The findings confirm that ovarian estradiol induces the senescence of hypothalamic astrocytes. The senescent astrocytes compromise the regulation of progesterone synthesis and GnRH secretion, which may contribute to aging-related declines in female reproductive function.

## MATERIALS AND METHODS

### Animals and treatment protocols

All C57BL/6J female mice were purchased from Slack Animal Co (Shanghai, China). Experimental mice were housed ( $\leq 5$  animals/cage) in a pathogen-free colony (IVC system, Tecniplast, Italy) and allowed free access to food and water. The colony was maintained under a 12-h light/12-h dark cycle with the temperature set at 24 °C. All protocols and procedures used in these studies were approved by the Institutional Animal Care and Use Committee of Fujian Medical University and in compliance with NIH's Guidelines for the Care and Use of Laboratory Animals (NIH Publication No. 85-23

Rev. 1985). Estrous cycles of the young-aged mice (3–4 months old) and middle-aged mice (9–10 months old) were monitored by daily vaginal smears. In this study only mice having at least two consecutive cycles of a regular 4–5 day estrous period were included. The selected mice received, under anesthesia, a bilateral ovariectomy (OVX) or OVX plus a pellet containing 0.25mg of 17 $\beta$ -estradiol (OVX+E<sub>2</sub>, Innovative Research of America, #NE-121), which undergoes a 90-day continual release and was subcutaneously implanted in the posterior neck. The OVX+E<sub>2</sub> group received another embedded 17 $\beta$ -estradiol sustained-release tablets 90 days later. Animals were transported to the operating room for tissue harvest at 9 months old.

### Transmission electron microscopy

The mice were anesthetized with 10% chloral hydrate and injected with normal saline, and their brains were immediately removed. The hypothalamic area was dissected (1 $\times$ 1 $\times$ 1 mm), immersed in 2.5% glutaraldehyde buffer, fixed in 1% tetroxide, dehydrated in the gradient concentration ethanol, and finally embedded in Epon812. The targeted subregion was observed under a transmission electron microscope (EM208, Royal Philips Electronics, Netherlands).

### Hypothalamus dissection and qPCR

The experiments were performed as to previously reported [4]. Briefly, animals were anaesthetized and brains were collected. The preoptic area anterior hypothalamus (POA-AH) for biochemical experiment. For POA-AH, the caudal border was made by a coronal cut just posterior to the entry point of the optic chiasm; the rostral border was exactly 3mm anterior. This coronal section (3 mm thick) was laid rostral side up on a chilled glass plate, then an isosceles triangle-shaped cut was made with its apex just under the midline of the corpus callosum and the 2 legs passing through the anterior commissure. Total RNA was extracted from the dissected hypothalamus and reversely transcribed into cDNA. The primer sets were presented in the Supplementary Table 1. Each reaction was performed in triplicate. Fold changes were calculated by  $2^{-\Delta\Delta t}$ , where  $\Delta Ct = Ct$  (target gene) -  $Ct$  (actin/GAPDH) and  $\Delta(\Delta Ct) = \Delta Ct$  (experimental groups) - mean  $\Delta Ct$ .

### Senescence-associated $\beta$ -galactosidase (SA- $\beta$ -Gal) assay combined with immunohistochemistry

The experiments were performed as to previously reported [4]. Briefly, the dissected brains were post-fixed in 4 % paraformaldehyde, dehydrolyzed in 30 % sucrose, and then sliced into sections (40 $\mu$ m). For SA- $\beta$ -Gal staining, sections were immersed in a SA- $\beta$ -Gal

staining solution. After incubation at 37 °C in the dark overnight, sections were washed and treated with 3 % H<sub>2</sub>O<sub>2</sub> for 10 min, and then washed. They were next blocked in a blocking buffer for 60 min, then incubated with Anti-Iba1 or anti-GFAP (Supplementary Table 2) in TBS for 24 h. They were then incubated with biotinylated second antibody at RT for 90 min. After being washed in TBS, these sections were further incubated in Vector Elite avidin peroxidase at RT for 1 h. Sections were stained with DAB for 1–10 min, then cover-slipped with a permanent mounting medium, and detected under a microscope.

### **Peroxidase assay combined with immunohistochemistry**

The sections were washed with TBS and then developed directly with DAB for 10 min. After another TBS wash, the brain sections were examined by immunohistochemistry.

### **Immunofluorescence**

The experiments were performed as to previously reported [4]. Briefly, sections were washed and then blocked at RT for 1 h. To detect astrocytes, the sections were incubated at 4 °C for 24 h with primary antibodies in TBS: polyclonal chicken anti-GFAP, polyclonal rabbit anti-GS, polyclonal rabbit anti-P16, and monoclonal mouse anti- $\gamma$ H2AX (Supplementary Table 2). The sections were then washed and incubated at RT for 1 h in a mixture of secondary antibodies. Afterwards, the sections were washed, mounted on glass slides, and then cover-slipped with prolong Gold anti-fade reagent.

### **Hypothalamic primary astrocyte cultures and conditioned medium**

The astrocytes were obtained from the brains of neonatal mice (d1–2, C57BL/6J). Hypothalamus and cortices were dissected, freed of meninges in an ice-cold salt ion buffer. Digestive enzyme was compounded using Papain Suspension (Worthington, Lakewood, NJ) and salt ion buffer. The separated brain tissue was placed in the filtered digestive enzyme and dissolved in an incubator with 5% CO<sub>2</sub> at 37°C for 20 min. Then, enzyme activity was blocked by an excess of fetal bovine serum (FBS, HyClone, Utah, USA). All of the enzymes were removed and tissues were mechanically dissociated in a DME/F12 medium (HyClone, Utah, USA) containing 10% FBS and 1% penicillin-streptomycin (HyClone, Utah, USA). After mechanical dissociation, cells were seeded and maintained in an incubator with 5% CO<sub>2</sub> at 37°C for 2 weeks in DME/F-12 containing 10% FBS and 1% penicillin-streptomycin

in poly-L-lysine coated 6-well or 24-well plates. The culture medium was refreshed twice a week. The purity of astrocytes was about 95% of GFAP-positive cells.

Prior to drug treatment, all astrocytes were subjected to steroid starvation for 24 hours in DME/F12 (supplemented with 5% of fetal bovine serum separated by charcoal; Sigma-Aldrich, F6765, St. Louis, MO). After steroid-starvation, some cultures were respectively treated for 48 h with 17 $\beta$ -estradiol (10<sup>-10</sup>M, 10<sup>-8</sup>M, 10<sup>-6</sup>M; Sigma-Aldrich, E2758, St. Louis, MO), Forskolin (10  $\mu$ M, 24 h), H89 (30  $\mu$ M, 24 h), 17 $\beta$ -estradiol (10<sup>-6</sup>M) + Forskolin, 17 $\beta$ -estradiol (10<sup>-6</sup>M) + H89, or estradiol-free DME/F12 culture media. The process of steroid starvation and drug treatment was repeated 4 times. Other cultures were respectively treated with 2-OHE<sub>2</sub> (20 nM) and 4-OHE<sub>2</sub> (20 nM) for 24 h before the medium refreshment. After 36 h, the collected media were cultured with the GT1-7 lines for 48 h.

### **Sample preparation and HPLC analysis**

The weighed sample was ground and suspended in a mixture of water and methanol (1:1). The sample was homogenized and then centrifuged by high-speed centrifugation in a vacuum. The residue was dissolved in water and methanol (1:1), filtered through a 0.2  $\mu$  ultracentrifuge filter (Merck Millipore, MA, USA) and prepared for HPLC analysis. The process was repeated in duplicate during HPLC analysis. Pure standards were used to optimize the HPLC conditions prior to sample analysis. HPLC was performed by Shanghai Institute of Organic Chemistry, Chinese Academy of Science.

### **Statistical analysis**

Data were presented as means  $\pm$  standard error (SEM) of a percent relative ratio. Statistical comparisons between 2 independent groups were analyzed by the unpaired Student's t-test; comparisons among 3 or more independent groups, were by a one-way analysis of variance (ANOVA), together with Kruskal-Wallis test where appropriate. Data were processed using GraphPad Software.  $p < 0.05$  was considered statistically significant.

### **Abbreviations**

HPO: hypothalamic-pituitary-ovarian axis; LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; E<sub>2</sub>: estradiol; ER $\alpha$ : estradiol receptor-alpha; PKA: protein kinase A; P450scc: cholesterol-side-chain cleavage enzyme; 3 $\beta$ -HSD: 3 $\beta$ -hydroxysteroid dehydrogenase; TGF: Transforming growth factor; OVX: ovariectomy; RP3V: rostral periventricular area of the third ventricle; SA- $\beta$ -Gal: senescence associated  $\beta$ -

galactosidase; 2-OHE<sub>2</sub>: 2-hydroxyestradiol; 4-OHE<sub>2</sub>: 4-hydroxyestradiol.

## AUTHOR CONTRIBUTIONS

Xiaoman Dai executed immunohistochemistry and molecular experiments, and wrote the manuscript; Luyan Hong performed the cell experiments and analyzed all the data; Hui Shen contributed to the animal maintenance; Qiang Du performed the animal surgery; Qinyong Ye provided substantial contributions to development of methodology; Jing Zhang and Xiaochun Chen conceived and designed the project, and prepared and revised the manuscript; and all authors read and commented on the manuscript.

## CONFLICTS OF INTEREST

All authors have no potential conflicts of interests or financial issues to declare.

## FUNDING

The study was funded by National Natural Science Foundation of China to Jing Zhang (No.81671400) and Fujian Province Health and Family Planning Youth Research Project to Xiaoman Dai (No.2018-1-45).

## REFERENCES

1. Cooper RL, Conn PM, Walker RF. Characterization of the LH surge in middle-aged female rats. *Biol Reprod.* 1980; 23:611–15.  
<https://doi.org/10.1095/biolreprod23.3.611>  
PMID:7192575
2. Scarbrough K, Wise PM. Age-related changes in pulsatile luteinizing hormone release precede the transition to estrous acyclicity and depend upon estrous cycle history. *Endocrinology.* 1990; 126:884–90.  
<https://doi.org/10.1210/endo-126-2-884>  
PMID:2404750
3. Zhang J, Yang LM, Pan XD, Lin N, Chen XC. Increased vesicular  $\gamma$ -GABA transporter and decreased phosphorylation of synapsin I in the rostral preoptic area is associated with decreased gonadotrophin-releasing hormone and c-Fos coexpression in middle-aged female mice. *J Neuroendocrinol.* 2013; 25:753–61.  
<https://doi.org/10.1111/jne.12050>  
PMID:23679216
4. Zhang J, Yang L, Lin N, Pan X, Zhu Y, Chen X. Aging-related changes in RP3V kisspeptin neurons predate the reduced activation of GnRH neurons during the early reproductive decline in female mice. *Neurobiol Aging.* 2014; 35:655–68.  
<https://doi.org/10.1016/j.neurobiolaging.2013.08.038>  
PMID:24112790
5. Lloyd JM, Hoffman GE, Wise PM. Decline in immediate early gene expression in gonadotropin-releasing hormone neurons during proestrus in regularly cycling, middle-aged rats. *Endocrinology.* 1994; 134:1800–05.  
<https://doi.org/10.1210/endo.134.4.8137745>  
PMID:8137745
6. Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K. Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. *Endocrinology.* 2007; 148:782–89.  
<https://doi.org/10.1210/en.2006-0774>  
PMID:17095591
7. Mohr MA, Wong AM, Tomm RJ, Soma KK, Micevych PE. Pubertal development of estradiol-induced hypothalamic progesterone synthesis. *Horm Behav.* 2019; 111:110–13.  
<https://doi.org/10.1016/j.yhbeh.2018.12.007>  
PMID:30552874
8. Micevych P, Sinchak K. Estradiol regulation of progesterone synthesis in the brain. *Mol Cell Endocrinol.* 2008; 290:44–50.  
<https://doi.org/10.1016/j.mce.2008.04.016>  
PMID:18572304
9. Prevot V, Croix D, Bouret S, Dutoit S, Tramu G, Stefano GB, Beauvillain JC. Definitive evidence for the existence of morphological plasticity in the external zone of the median eminence during the rat estrous cycle: implication of neuro-glio-endothelial interactions in gonadotropin-releasing hormone release. *Neuroscience.* 1999; 94:809–19.  
[https://doi.org/10.1016/S0306-4522\(99\)00383-8](https://doi.org/10.1016/S0306-4522(99)00383-8)  
PMID:10579572
10. Baroncini M, Allet C, Leroy D, Beauvillain JC, Francke JP, Prevot V. Morphological evidence for direct interaction between gonadotrophin-releasing hormone neurones and astroglial cells in the human hypothalamus. *J Neuroendocrinol.* 2007; 19:691–702.  
<https://doi.org/10.1111/j.1365-2826.2007.01576.x>  
PMID:17680884
11. Prevot V, Dehouck B, Poulain P, Beauvillain JC, Buée-Scherrer V, Bouret S. Neuronal-glia-endothelial interactions and cell plasticity in the postnatal hypothalamus: implications for the neuroendocrine control of reproduction. *Psychoneuroendocrinology.* 2007 (Suppl 1); 32:S46–51.  
<https://doi.org/10.1016/j.psyneuen.2007.03.018>  
PMID:17629628
12. Moeller-Gnangra H, Ernst J, Pfeifer M, Heger S. ErbB4 point mutation in CU3 inbred rats affects gonadotropin-releasing-hormone neuronal function via




- compromised neuregulin-stimulated prostaglandin E2 release from astrocytes. *Glia*. 2019; 67:309–20.  
<https://doi.org/10.1002/glia.23541>  
PMID:30485552
13. Gallo F, Morale MC, Farinella Z, Avola R, Marchetti B. Growth factors released from astroglial cells in primary culture participate in the cross talk between luteinizing hormone-releasing hormone (LHRH) neurons and astrocytes. Effects on LHRH neuronal proliferation and secretion. *Ann N Y Acad Sci*. 1996; 784:513–16.  
<https://doi.org/10.1111/j.1749-6632.1996.tb16272.x>  
PMID:8651608
  14. Galbiati M, Zanisi M, Messi E, Cavarretta I, Martini L, Melcangi RC. Transforming growth factor-beta and astrocytic conditioned medium influence luteinizing hormone-releasing hormone gene expression in the hypothalamic cell line GT1. *Endocrinology*. 1996; 137:5605–09.  
<https://doi.org/10.1210/endo.137.12.8940390>  
PMID:8940390
  15. Buchanan CD, Mahesh VB, Brann DW. Estrogen-astrocyte-luteinizing hormone-releasing hormone signaling: a role for transforming growth factor-beta(1). *Biol Reprod*. 2000; 62:1710–21.  
<https://doi.org/10.1095/biolreprod62.6.1710>  
PMID:10819775
  16. Micevych P, Soma KK, Sinchak K. Neuroprogesterone: key to estrogen positive feedback? *Brain Res Brain Res Rev*. 2008; 57:470–80.  
<https://doi.org/10.1016/j.brainresrev.2007.06.009>  
PMID:17850878
  17. Sohal RS, Brunk UT. Lipofuscin as an indicator of oxidative stress and aging. *Adv Exp Med Biol*. 1989; 266:17–26.  
[https://doi.org/10.1007/978-1-4899-5339-1\\_2](https://doi.org/10.1007/978-1-4899-5339-1_2)  
PMID:2486150
  18. Geng YQ, Guan JT, Xu XH, Fu YC. Senescence-associated beta-galactosidase activity expression in aging hippocampal neurons. *Biochem Biophys Res Commun*. 2010; 396:866–69.  
<https://doi.org/10.1016/j.bbrc.2010.05.011>  
PMID:20457127
  19. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE. Ink4a/Arf expression is a biomarker of aging. *J Clin Invest*. 2004; 114:1299–307.  
<https://doi.org/10.1172/JCI22475>  
PMID:15520862
  20. Zwart SR, Jessup JM, Ji J, Smith SM. Saturation diving alters folate status and biomarkers of DNA damage and repair. *PLoS One*. 2012; 7:e31058.  
<https://doi.org/10.1371/journal.pone.0031058>  
PMID:22347427
  21. Scarpato R, Verola C, Fabiani B, Bianchi V, Saggese G, Federico G. Nuclear damage in peripheral lymphocytes of obese and overweight Italian children as evaluated by the gamma-H2AX focus assay and micronucleus test. *FASEB J*. 2011; 25:685–93.  
<https://doi.org/10.1096/fj.10-168427>  
PMID:21068397
  22. Kuo J, Micevych P. Neurosteroids, trigger of the LH surge. *J Steroid Biochem Mol Biol*. 2012; 131:57–65.  
<https://doi.org/10.1016/j.jsbmb.2012.01.008>  
PMID:22326732
  23. Micevych P, Bondar G, Kuo J. Estrogen actions on neuroendocrine glia. *Neuroendocrinology*. 2010; 91:211–22.  
<https://doi.org/10.1159/000289568>  
PMID:20332598
  24. Nequin LG, Alvarez J, Schwartz NB. Measurement of serum steroid and gonadotropin levels and uterine and ovarian variables throughout 4 day and 5 day estrous cycles in the rat. *Biol Reprod*. 1979; 20:659–70.  
<https://doi.org/10.1095/biolreprod20.3.659>  
PMID:572241
  25. Kunzler J, Youmans KL, Yu C, Ladu MJ, Tai LM. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice. *Neurosci Lett*. 2014; 560:131–36.  
<https://doi.org/10.1016/j.neulet.2013.12.032>  
PMID:24368217
  26. Xing Y, Jia JP, Ji XJ, Tian T. Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer's disease. *Prog Neurobiol*. 2013; 111:53–74.  
<https://doi.org/10.1016/j.pneurobio.2013.09.006>  
PMID:24096044
  27. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. *Biochim Biophys Acta*. 2006; 1766:63–78.  
<https://doi.org/10.1016/j.bbcan.2006.03.001>  
PMID:16675129
  28. Li KM, Todorovic R, Devanesan P, Higginbotham S, Köfeler H, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. *Carcinogenesis*. 2004; 25:289–97.  
<https://doi.org/10.1093/carcin/bgg191>  
PMID:14578156
  29. Tsuchiya Y, Nakajima M, Takagi S, Katoh M, Zheng W, Jefcoate CR, Yokoi T. Binding of steroidogenic factor-1

- to the regulatory region might not be critical for transcriptional regulation of the human CYP1B1 gene. *J Biochem*. 2006; 139:527–34.  
<https://doi.org/10.1093/jb/mvj055>  
PMID:16567417
30. Oesch-Bartlomowicz B, Oesch F. Cytochrome-P450 phosphorylation as a functional switch. *Arch Biochem Biophys*. 2003; 409:228–34.  
[https://doi.org/10.1016/S0003-9861\(02\)00558-1](https://doi.org/10.1016/S0003-9861(02)00558-1)  
PMID:12464263
31. Sarchielli E, Comeglio P, Squecco R, Ballerini L, Mello T, Guarnieri G, Idrizaj E, Mazzanti B, Vignozzi L, Gallina P, Maggi M, Vannelli GB, Morelli A. Tumor Necrosis Factor- $\alpha$  Impairs Kisspeptin Signaling in Human Gonadotropin-Releasing Hormone Primary Neurons. *J Clin Endocrinol Metab*. 2017; 102:46–56.  
<https://doi.org/10.1210/jc.2016-2115>  
PMID:27736314
32. Igaz P, Salvi R, Rey JP, Glauser M, Pralong FP, Gaillard RC. Effects of cytokines on gonadotropin-releasing hormone (GnRH) gene expression in primary hypothalamic neurons and in GnRH neurons immortalized conditionally. *Endocrinology*. 2006; 147:1037–43.  
<https://doi.org/10.1210/en.2005-0729>  
PMID:16282355
33. Stephens SB, Tolson KP, Rouse ML Jr, Poling MC, Hashimoto-Partyka MK, Mellon PL, Kauffman AS. Absent Progesterone Signaling in Kisspeptin Neurons Disrupts the LH Surge and Impairs Fertility in Female Mice. *Endocrinology*. 2015; 156:3091–97.  
<https://doi.org/10.1210/en.2015-1300>  
PMID:26076042
34. Preuss TG, Gurer-Orhan H, Meerman J, Ratte HT. Some nonylphenol isomers show antiestrogenic potency in the MVLN cell assay. *Toxicol In Vitro*. 2010; 24:129–34.  
<https://doi.org/10.1016/j.tiv.2009.08.017>  
PMID:19720131
35. Ropero AB, Pang Y, Alonso-Magdalena P, Thomas P, Nadal A. Role of ER $\beta$  and GPR30 in the endocrine pancreas: A matter of estrogen dose. *Steroids*. 2012; 77:951–58.  
<https://doi.org/10.1016/j.steroids.2012.01.015>  
PMID:22306576
36. Mydlarski MB, Liberman A, Schipper HM. Estrogen induction of glial heat shock proteins: implications for hypothalamic aging. *Neurobiol Aging*. 1995; 16:977–81.  
[https://doi.org/10.1016/0197-4580\(95\)02018-7](https://doi.org/10.1016/0197-4580(95)02018-7)  
PMID:8622790
37. Swartz WJ, Eroschenko VP. Neonatal exposure to technical methoxychlor alters pregnancy outcome in female mice. *Reprod Toxicol*. 1998; 12:565–73.  
[https://doi.org/10.1016/S0890-6238\(98\)00041-0](https://doi.org/10.1016/S0890-6238(98)00041-0)  
PMID:9875691
38. Chen C, Kuo J, Wong A, Micevych P. Estradiol modulates translocator protein (TSPO) and steroid acute regulatory protein (StAR) via protein kinase A (PKA) signaling in hypothalamic astrocytes. *Endocrinology*. 2014; 155:2976–85.  
<https://doi.org/10.1210/en.2013-1844>  
PMID:24877623
39. Lan YL, Zhao J, Li S. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease. *J Alzheimers Dis*. 2015; 43:1137–48.  
<https://doi.org/10.3233/JAD-141875>  
PMID:25159676
40. Morale MC, Serra PA, L'episcopo F, Tirolo C, Caniglia S, Testa N, Gennuso F, Giaquinta G, Rocchitta G, Desole MS, Miele E, Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. *Neuroscience*. 2006; 138:869–78.  
<https://doi.org/10.1016/j.neuroscience.2005.07.060>  
PMID:16337092
41. Liu R, Yang SH. Window of opportunity: estrogen as a treatment for ischemic stroke. *Brain Res*. 2013; 1514:83–90.  
<https://doi.org/10.1016/j.brainres.2013.01.023>  
PMID:23340160
42. Engler-Chiurazzi EB, Brown CM, Povroznik JM, Simpkins JW. Estrogens as neuroprotectants: estrogenic actions in the context of cognitive aging and brain injury. *Prog Neurobiol*. 2017; 157:188–211.  
<https://doi.org/10.1016/j.pneurobio.2015.12.008>  
PMID:26891883
43. Goodson JL, Saldanha CJ, Hahn TP, Soma KK. Recent advances in behavioral neuroendocrinology: insights from studies on birds. *Horm Behav*. 2005; 48:461–73.  
<https://doi.org/10.1016/j.yhbeh.2005.04.005>  
PMID:15896792
44. Kang SS, Kim SR, Leonhardt S, Jarry H, Wuttke W, Kim K. Effect of interleukin-1 $\beta$  on gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in castrated male rats. *J Neuroendocrinol*. 2000; 12:421–29.  
<https://doi.org/10.1046/j.1365-2826.2000.00466.x>  
PMID:10792581

SUPPLEMENTARY MATERIALS


Supplementary Figures




**Supplementary Figure 1.** (A) Peroxidase staining (brown) in the astrocyte of RP3V region in mice at different ages (up pictures), black arrows representing peroxidase. GFAP (black) and peroxidase (brown) double staining in the astrocyte of the RP3V region of the hypothalamus in mice at different ages (down pictures), black arrows representing peroxidase-positive astrocytes. n=5, Scale bar =100 μm. (B) CCK8 assay of astrocyte cultured with different estradiol concentrations. 10<sup>-4</sup>M E<sub>2</sub> inhibited cell growth at 24h, 48h and 72h, n=10, \*\*p<0.01. (C) Detection of the mRNA levels of *p16* and *p21* under different estradiol concentrations in the cortex astrocyte (n = 3-4).



(D) Dual-label immunohistochemistry showing astrocytes (brown) and SA-β-Gal staining (blue) with three different estradiol concentrations ( $10^{-10}$ M,  $10^{-8}$ M,  $10^{-6}$ M), scale bar=100μm; dual-label immunofluorescent showing astrocyte (green) and γ-H2AX (red) with different estradiol concentrations, white arrows representing γ-H2AX-positive astrocytes. Estradiol did not affect the percentage of the SA-β-Gal positive cells in different estradiol concentrations. Estradiol decreased the percentage of γ-H2AX-positive astrocytes in different estradiol concentrations (\*\* $p < 0.01$ ). Estradiol decreased the average fluorescence intensity in different estradiol concentrations, (\* $p < 0.05$  for  $10^{-10}$ M and \*\* $p < 0.01$  for  $10^{-6}$ M). Scale bar=50μm. n=3. (E) Detection of *3β-HSD* mRNA levels in astrocyte from hypothalamus and cortex under different estradiol concentrations. Only  $10^{-6}$ M estradiol increased the expression of *3β-HSD* gene in hypothalamic astrocytes. Estradiol decreased the expression of *3β-HSD* with different estradiol concentrations in cortex astrocytes (n = 3-4). The p-value was determined by One-way ANOVA: \* $p < 0.05$ , \*\*  $p < 0.01$ .



**Supplementary Figure 2.** (A) Effects of estrous cycle on the mRNA expression of *CYP1A1*, *CYP1A2* and *CYP1B1* gene in the cortex. The p-value was determined by One-way ANOVA, ns, metestrus compared with proestrus (n=3). (B) Expression of PKA and p-PKA in the cortex of proestrus and metestrus at 3 months of age. Western blot analysis was normalized by GAPDH as the loading control. ns, metestrus compared with proestrus (n = 6). (C) Detection of *CYPs* mRNA levels under different estradiol concentrations in the cortex astrocyte (n = 3-4). The p-value of (a) and (b) was determined by Student's t test.

**A**

**Supplementary Figure 3. (A)** Dual-label immunohistochemistry showing astrocytes (brown) and SA-β-Gal staining (blue) with treatment of 10<sup>-6</sup>M estradiol, 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub>. Black arrows represent SA-β-Gal-positive astrocytes. The number of SA-β-gal-positive cells in 10<sup>-6</sup>M E<sub>2</sub> group was much smaller than that in 2-OHE<sub>2</sub> and 4-OHE<sub>2</sub> groups, respectively (n=5). The *p*-value was determined by One-way ANOVA: \*\* *p* < 0.01. Scale bar=100μm.

## Supplementary Tables

**Supplementary Table 1. Primer sequences.**

Gene	Primer sequences
CYP1A1	Forward, 5'GGTTAACCATGACCGGGAAC3' Reverse, 5'TGCCCAAACCAAAGAGAGTGA3'
CYP1A2	Forward, 5'ACATTCCCAAGGAGCGCTGTATCT3' Reverse, 5'GTCGATGGCCGAGTTGTTATTGGT3'
CYP1B1	Forward, 5'GTGGCTGCTCATCCTCTTTACC3' Reverse, 5'CCCACAACCTGGTCCAAC3'
P450 <sub>ssc</sub>	Forward, 5'GACCAAGTTCAGCCTCATCC3' Reverse, 5'CTCCAGCCTTCAGTTCACAG3'
3 $\beta$ -HSD	Forward, 5'TTGTCATCCACACTGCTGCT3' Reverse, 5'TGGCACACTTGCTTGAACAC3'
p16	Forward, 5'CCCAACGCCCCGAAC3' Reverse, 5'GCAGAAGAGCTGCTACGTGAA3'
p21	Forward, 5'GGCAGACCAGCCTGACAGAT3' Reverse, 5'TTCAGGGTTTTCTCTTGCAGAAG3'
TNF- $\alpha$	Forward, 5'GACGTGGAAGTGGCAGAAGAG3' Reverse, 5'TTGGTGGTTTTGTGAGTGTGAG3'
IL-1 $\beta$	Forward, 5'TTCAGGCAGGCAGTATCACTC3' Reverse, 5'GAAGGTCCACGGGAAAGACAC3'
IL-6	Forward, 5'TAGTCCTTCCTACCCCAATTTCC3' Reverse, 5'TTGGTCCTTAGCCACTCCTTC3'
IL-8	Forward, 5'TCGAGACCATTTACTGCAACAG3' Reverse, 5'CATTGCCGGTGGAAATTCCTT3'
TGF- $\alpha$	Forward, 5'GGAACCTGCCGGTTTTTGG3' Reverse, 5'CACAGCGAACACCCACGTA3'
TGF- $\beta$ 1	Forward, 5'CTCCCGTGGCTTCTAGTGC3' Reverse, 5'GCCTTAGTTTTGGACAGGATCTG3'
IGF-1	Forward, 5'AAATCAGCAGCCTTCCAAC3' Reverse, 5'GCACTTCCTCTACTTGTGTTCTT3'
GAPDH	Forward, 5'CAGTGGCAAAGTGGAGATTGTTG3' Reverse, 5'CTCGCTCCTGGAAGATGGTGAT3'

**Supplementary Table 2. Antibodies used in the study.**

Antibodies	Manufacturer	Catalogue No.	Dilution
Anti-Iba1	Wako	019-19741	1:1000 for IHC
Anti- GFAP	Covance	SMI-21R-100	1:1000for IHC
Anti- GFAP	Covance	PCK-591P-100	1:2000 for IF
Anti-GS	MilliporeSigma	G2781	1:5000 for IF
Anti-P16	Santa Cruz Biotechnology	sc-1207	1:1000 for IF
Anti- $\gamma$ H2AX	Abcam	ab26350	1:1000 for IF
Anti-PKA	Cell Signaling Technology	#5842	1:1000 for WB
Anti-p-PKA	Cell Signaling Technology	#5661	1:1000 for WB
Anti-GAPDH	Abcam	ab127428	1:5000 for WB